Roche launches new assay for breast and gastric cancer detection
Roche
Fr.239.20
08:00 24/04/24
Roche announced the launch of the new ‘VENTANA HER2 Dual ISH DNA Probe Cocktail’ assay on Tuesday, for the detection of the HER2 biomarker in breast and gastric cancer.
The Swiss pharmaceutical giant described HER2 - human epidermal growth factor receptor 2 - as an “important biomarker” found in breast and gastric cancers.
It said its detection and inhibition could help to more effectively manage those aggressive cancers.
The VENTANA HER2 Dual ISH DNA Probe Cocktail assay was designed to be completed within the same day, Roche explained, providing clinicians the ability to get results back quicker than the most common methods of confirmatory testing for HER2.
Results could be read using light microscopy, eliminating the need for a specialised fluorescence microscope.
“The new VENTANA HER2 Dual ISH assay advances Roche's commitment to personalised healthcare by delivering critical information on treatment options for breast and gastric cancer patients faster,” said Roche Diagnostics chief executive officer Michael Heuer.
“Quick results are crucial in the fight against cancer, and every additional day that a clinician and a patient must wait for test results is a day too long.”
This assay was currently being launched in Europe, the Middle East and Africa, as well as Latin America and the Asia Pacific region.
It would be submitted to the US Food and Drug Administration for approval, Roche confirmed.